The PMDA's view on the limited pipeline of nephrology drugs in Japan

Affiliations

¹ Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. Electronic address: motanaka-tky@umin.ac.jp.
² Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.

Free article

Comment

Mototsugu Tanaka et al. Kidney Int. 2021 Jul.

Free article

. 2021 Jul;100(1):241-242.

doi: 10.1016/j.kint.2021.03.034.

¹ Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. Electronic address: motanaka-tky@umin.ac.jp.
² Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.

No abstract available

Comment on

Innovating and invigorating the clinical trial infrastructure for glomerular diseases.
Barisoni L, Barratt J, Campbell K, Eva L, Gillespie BS, Gipson D, Huber T, Jardine M, Kamil E, Kretzler M, Lee L, Levtchenk E, Mehr AP, Nachman PH, Oh J, Saleem M, Shankland SJ, Smith K, Smokler I, Smoyer W, Tarnoff J, Thompson A, Trachtman H, Udani S, Vivarelli M, Walker P, West M, Rovin BH. Barisoni L, et al. Kidney Int. 2021 Mar;99(3):519-523. doi: 10.1016/j.kint.2020.09.038. Kidney Int. 2021. PMID: 33637197 No abstract available.